GUANGZHOU, China, April 13, 2025 – Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a prominent provider of Internet healthcare solutions, participated in the “AI Empowers Biopharma” exchange forum on April 3, 2025. The event, hosted by the Guangzhou Development District Talent Education Group, brought together 28 companies to discuss the latest AI applications in healthcare.
Guo Zhi, Fangzhou’s Senior Vice President of Technology, stated during the panel that Fangzhou has systematically tackled key healthcare delivery challenges by creating their AI + H2H Smart Healthcare Ecosystem. This innovative approach extends vital services, such as chronic disease management, patient education, and medication delivery, directly to patients’ homes, thereby enhancing care accessibility and timeliness while improving the overall treatment experience.
Mitigate AI hallucinations
The company also introduced its unique framework for reducing AI hallucinations in medical contexts, which combines a self-built training platform with a specialized medical knowledge base and data sandbox. This framework supports Fangzhou’s “AI Agent Matrix,” which provides continuous diagnostic support, intelligent customer service tools, and AI-supported health content creation, improving care access and lowering operating costs.
Blueprint for Vertical AI Leadership
Looking ahead, Fangzhou plans to increase its focus on AI + Healthcare, utilizing its established H2H Smart Healthcare Ecosystem to further integrate AI into online healthcare applications. The Company aims to leverage opportunities like this panel to enhance collaboration with biopharmaceutical companies and research institutions, promoting synergistic development between regional biomedicine and smart healthcare.
AI-Powered Growth Strategy
Fangzhou’s growth strategy is centered on using advanced AI technologies like DeepSeek-V3 and strengthening partnerships with industry leaders like Tencent Health and Tencent Cloud. These efforts aim to expand the possibilities of AI-driven healthcare, reinforce the Company’s technological leadership, and accelerate the market adoption of its innovations, all to provide better care experiences and improved solutions for patients and users.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is a leading online chronic disease management platform in China, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company focuses on delivering customized medical care and precision medicine solutions. For more information, visit .
About the “AI Empowers Biopharma” Exchange Panel
The Guangzhou Development District is intensifying its efforts to become a leader in biopharma innovation, with the “AI Empowers Biopharma” exchange panel highlighting AI-driven antibody research, quantum computing for drug development, and smart healthcare ecosystems.
Media Contact
For more information or to arrange interviews, please contact:
Xingwei Zhao Associate Director of Public Relations Email:
Disclaimer: This press release includes forward-looking statements. Actual results may differ significantly from those projected due to various factors. Readers are advised not to rely excessively on these statements.
SOURCE Fangzhou Inc.
“`